Impact of First-Year Dose Modifications of Acalabrutinib in Patients with CLL

Acalabrutinib, a second-generation, covalent Bruton tyrosine kinase inhibitor, demonstrated progression-free survival benefit and/or favorable tolerability vs comparators in patients with treatment-naive and relapsed/refractory CLL. This study assesses the impact of dose modifications or discontinuations that occur in the first year of acalabrutinib in treatment-naive patients on overall survival (OS), in patients with treatment-naive CLL, and in patients with relapsed/refractory CLL. In this MEDtalk, Alessandra Tedeschi presents the results.